NASDAQ:OSA

ProSomnus (OSA) Stock Forecast, Price & News

$0.90

-0.02 (-2.17%)

(As of 10/3/2023 ET)

Compare

Today's Range: $0.88
▼
$0.98
50-Day Range: $0.90
▼
$2.12
52-Week Range: $0.88
▼
$9.41

Volume: 10,643 shs
Average Volume: 14,347 shs
Market Capitalization: $14.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

ProSomnus MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 677.8% Upside
$7.00 Price Target
Short Interest: Healthy
0.77% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.13
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.22) to ($0.50) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

766th out of 966 stocks

Surgical & Medical Instruments Industry

78th out of 95 stocks

3.5

Analyst's Opinion

Consensus Rating
ProSomnus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, ProSomnus has a forecasted upside of 677.8% from its current price of $0.90.
Amount of Analyst Coverage
ProSomnus has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.77% of the float of ProSomnus has been sold short.
Short Interest Ratio / Days to Cover
ProSomnus has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ProSomnus has recently increased by 13.65%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
ProSomnus does not currently pay a dividend.
Dividend Growth
ProSomnus does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OSA.

1.7

News and Social Media Coverage

News Sentiment
ProSomnus has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for ProSomnus this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 1 people have added ProSomnus to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ProSomnus insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.50% of the stock of ProSomnus is held by insiders.
Percentage Held by Institutions
Only 7.94% of the stock of ProSomnus is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ProSomnus are expected to grow in the coming year, from ($1.22) to ($0.50) per share.

See Top Rated MarketRank™ Stocks Here

About ProSomnus (NASDAQ:OSA) Stock

ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolarygologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.

OSA Price History

30 days | 90 days | 365 days | Advanced Chart

OSA Stock News Headlines

October 3, 2023 | finance.yahoo.com

ProSomnus Announces Participation in the 2023 Roth Capital Healthcare Opportunities Conference

October 3, 2023 | americanbankingnews.com

Head to Head Analysis: Plus Therapeutics (NASDAQ:PSTV) vs. ProSomnus (NASDAQ:OSA)

October 4, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.

October 3, 2023 | americanbankingnews.com

Comparing Plus Therapeutics (NASDAQ:PSTV) & ProSomnus (NASDAQ:OSA)

September 27, 2023 | msn.com

Roth MKM Maintains ProSomnus (OSA) Buy Recommendation

September 27, 2023 | americanbankingnews.com

ProSomnus (NASDAQ:OSA) Given New $4.00 Price Target at Roth Mkm

September 26, 2023 | markets.businessinsider.com

Roth MKM Maintains Buy Rating for ProSomnus: Here's What You Need To Know

September 21, 2023 | finance.yahoo.com

ProSomnus, Inc. (OSA)

October 4, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

September 21, 2023 | finance.yahoo.com

ProSomnus Secures $10 Million to Drive Growth

September 21, 2023 | msn.com

ProSomnus closes $10M preferred equity round

September 21, 2023 | msn.com

EXCLUSIVE: Sleep Disorder Focused ProSomnus Raises $10M To Fuel Growth, Optimize Operations

September 21, 2023 | finance.yahoo.com

ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations

September 14, 2023 | finance.yahoo.com

ProSomnus Precision Obstructive Sleep Apnea Devices to be Featured in Scientific Abstracts and Podium Presentations at Upcoming Medical Conferences

September 14, 2023 | finance.yahoo.com

ProSomnus Showcasing Sleep Apnea Treatment at Medical Conferences

September 6, 2023 | finance.yahoo.com

ICR Hosts ProSomnus CEO Len Liptak on the Welcome to the Arena Podcast

August 23, 2023 | msn.com

EXCLUSIVE: ProSomnus' Device Therapy Better Than Philip's Device(s) For Sleep-Related Breathing Disorder, Study Shows

August 23, 2023 | finance.yahoo.com

Updated Clinical Trial Data Indicates Precision Oral Appliance Therapy with ProSomnus Devices is Non-Inferior to CPAP Therapy for the Treatment of Moderate to Severe Obstructive Sleep Apnea

August 23, 2023 | finance.yahoo.com

ProSomnus Updated Clinical Trial Data Indicates Therapy is Non-Inferior to CPAP

August 3, 2023 | finance.yahoo.com

EXCLUSIVE: ProSomnus Reports Much Smaller Than Expected Q2 Loss, Revenues Inline With Consensus

August 3, 2023 | finance.yahoo.com

ProSomnus Sees Record Revenue in Second Quarter

August 3, 2023 | finance.yahoo.com

ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results

July 31, 2023 | markets.businessinsider.com

Craig-Hallum Sticks to Its Buy Rating for ProSomnus (OSA)

July 13, 2023 | finance.yahoo.com

ProSomnus Sleep Apnea Trial Compares Precision Therapy to Nerve Stimulation

July 13, 2023 | finance.yahoo.com

ProSomnus to Design Head-to-Head Clinical Trial vs. Hypoglossal Nerve Stimulation

See More Headlines

Receive OSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProSomnus and its competitors with MarketBeat's FREE daily newsletter.

OSA Company Calendar

Last Earnings: 8/03/2023
Today: 10/04/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical Devices
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OSA
CUSIP: N/A
CIK: 1934064
Web: www.ProSomnus.com
Phone: 844-537-5337
Fax: N/A
Employees: 129
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.00
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +677.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,140,000.00
Net Margins: N/A
Pretax Margin: -31.14%
Return on Equity: N/A
Return on Assets: -48.65%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.29
Quick Ratio: 1.15

Sales & Book Value

Annual Sales: $19.39 million
Price / Sales: 0.75
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.28) per share
Price / Book: -0.70

Miscellaneous

Outstanding Shares: 16,060,000
Free Float: 14,693,000
Market Cap: $14.45 million
Optionable: Not Optionable
Beta: -0.08

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Leonard Liptak (Age 48)
Co-Founder, CEO & Director
Comp: $965.35k

Mr. Sung Kim (Age 41)
Co-Founder & CTO
Comp: $454.63k

Ms. Laing F. Rikkers
Co-founder & Exec. Chairman

Mr. Brian B. Dow (Age 54)
Chief Financial Officer

Dr. John E. Remmers M.D.
Chief Scientist

Ms. Heather Whalen
VP of Global Marketing Services

Dr. Shouresh Charkhandeh D.D.S.
Global Scientific Committee Chair

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

OSA Stock - Frequently Asked Questions

Should I buy or sell ProSomnus stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProSomnus in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OSA shares.
View OSA analyst ratings or view top-rated stocks.
What is ProSomnus' stock price forecast for 2023?: 3 Wall Street analysts have issued 12-month price targets for ProSomnus' shares. Their OSA share price forecasts range from $4.00 to $10.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 677.8% from the stock's current price.
View analysts price targets for OSA or view top-rated stocks among Wall Street analysts.
How have OSA shares performed in 2023?: ProSomnus' stock was trading at $5.56 at the start of the year. Since then, OSA stock has decreased by 83.8% and is now trading at $0.90.
View the best growth stocks for 2023 here.
When is ProSomnus' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our OSA earnings forecast.
How were ProSomnus' earnings last quarter?: ProSomnus, Inc. (NASDAQ:OSA) announced its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.12. The business earned $6.93 million during the quarter, compared to analyst estimates of $6.56 million.

What is ProSomnus' stock symbol?: ProSomnus trades on the NASDAQ under the ticker symbol "OSA."
How do I buy shares of ProSomnus?: Shares of OSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ProSomnus' stock price today?: One share of OSA stock can currently be purchased for approximately $0.90.
How much money does ProSomnus make?: ProSomnus (NASDAQ:OSA) has a market capitalization of $14.45 million and generates $19.39 million in revenue each year.
How many employees does ProSomnus have?: The company employs 129 workers across the globe.
How can I contact ProSomnus?: ProSomnus' mailing address is Suite A-2F 555 Shihui Road Songjiang District, Shanghai F4, 201100. The official website for the company is www.ProSomnus.com. The company can be reached via phone at 844-537-5337 or via email at investors@prosomnus.com.

This page (NASDAQ:OSA) was last updated on 10/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ProSomnus (OSA) Stock Forecast, Price & News

ProSomnus MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About ProSomnus (NASDAQ:OSA) Stock

OSA Price History

OSA Stock News Headlines

OSA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

OSA Stock - Frequently Asked Questions

Overall MarketRank^™